Background: Postmarketing research has explored the optimal application schedule of
imiquimod 5% cream for treatment of external anogenital warts. Objectives: We systemically …

Our objective was to determine the efficacy and safety of imiquimod 5% cream in the
treatment of external genital/perianal warts in an open-label Phase IIIB trial. Patients applied …

With the licensing of the new drug Imiquimod cream 5%(AldaraTM 3M Health Care) for the
treatment of anogenital warts and its inclusion into clinic guidelines, a case note review audit …

Objective. To evaluate if new imiquimod formulations using a shorter treatment duration are
safe and efficacious to treat anogenital warts. Methods. In two studies 534 women≥ 12 …

Our objective was to determine the optimal duration of treatment with imiquimod for external
genital warts over 4, 8, 12 or 16 weeks. A total of 120 women with a history of genital warts …

Objective: To investigate the efficacy and safety of imiquimod 5% cream in the treatment of
anogenital warts in a female population. Methods: In two open-label studies, female patients …

Objective To compare the safety and effectiveness of 5% and 1% imiquimod cream with
vehicle cream in the treatment of external anogenital warts. Design Randomized, double …

Imiquimod 5% cream (Aldara, Graceway Pharmaceuticals) is an immune response modifier
used for the topical treatment of anogenital warts in non-HIV-infected patients. Several …

Objective To review published randomised controlled trials to assess the benefit and harm of
imiquimod in the treatment of external genital warts. Data sources MEDLINE (1966 …

This study aims to evaluate the effectiveness of imiquimod treatment of external anogenital
warts and analyse its possible relationship with patient treatment satisfaction and …